Enhanced Recovery Protocol for Laparoscopic Sleeve Gastrectomy: Are Narcotics Necessary?
Bariatric surgery
ERAS
Enhanced recovery after surgery
Minimally invasive surgery
Narcotic
Opioid
Sleeve gastrectomy
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
30
10
2018
accepted:
19
12
2018
pubmed:
30
1
2019
medline:
15
8
2020
entrez:
30
1
2019
Statut:
ppublish
Résumé
Enhanced recovery after surgery (ERAS) protocols have improved patient experience and outcomes in a variety of fields, including bariatric surgery. Given the increasing opioid epidemic in the USA, we sought to determine the impact of our own ERAS protocol on narcotic usage following laparoscopic sleeve gastrectomy. Retrospective chart review was performed on patients undergoing primary laparoscopic sleeve gastrectomy for 6 months before and after implementation of an ERAS protocol. Our protocol strongly discouraged the use of narcotics in the postoperative period. Specific outcomes of interest were postoperative narcotic usage, length of stay, complications, and readmissions. Patient characteristics were similar in the two groups. ERAS implementation did not correlate with changes in length of stay, complications, or readmissions. However, ERAS implementation was associated with dramatic reductions in the use of intravenous narcotics (100% vs 47%, p < 0.01) and oral schedule 2 narcotics (56% vs 6%, p < 0.01), with an increase in the usage of tramadol (0% vs 36%, p < 0.01). After ERAS implementation, 52% of patients were managed without the use of schedule 2 narcotics (0% pre-ERAS, p < 0.01) and 33% received no narcotics of any kind (0% pre-ERAS, p < 0.01). Implementation of an ERAS protocol for laparoscopic sleeve gastrectomy is associated with a dramatic reduction in the use of narcotics in the postoperative period. This has implementation for the usage of narcotics for laparoscopic surgery and potential elimination of narcotics for certain patients and procedures.
Sections du résumé
BACKGROUND
Enhanced recovery after surgery (ERAS) protocols have improved patient experience and outcomes in a variety of fields, including bariatric surgery. Given the increasing opioid epidemic in the USA, we sought to determine the impact of our own ERAS protocol on narcotic usage following laparoscopic sleeve gastrectomy.
METHODS
Retrospective chart review was performed on patients undergoing primary laparoscopic sleeve gastrectomy for 6 months before and after implementation of an ERAS protocol. Our protocol strongly discouraged the use of narcotics in the postoperative period. Specific outcomes of interest were postoperative narcotic usage, length of stay, complications, and readmissions.
RESULTS
Patient characteristics were similar in the two groups. ERAS implementation did not correlate with changes in length of stay, complications, or readmissions. However, ERAS implementation was associated with dramatic reductions in the use of intravenous narcotics (100% vs 47%, p < 0.01) and oral schedule 2 narcotics (56% vs 6%, p < 0.01), with an increase in the usage of tramadol (0% vs 36%, p < 0.01). After ERAS implementation, 52% of patients were managed without the use of schedule 2 narcotics (0% pre-ERAS, p < 0.01) and 33% received no narcotics of any kind (0% pre-ERAS, p < 0.01).
CONCLUSION
Implementation of an ERAS protocol for laparoscopic sleeve gastrectomy is associated with a dramatic reduction in the use of narcotics in the postoperative period. This has implementation for the usage of narcotics for laparoscopic surgery and potential elimination of narcotics for certain patients and procedures.
Identifiants
pubmed: 30693426
doi: 10.1007/s11605-018-04091-y
pii: 10.1007/s11605-018-04091-y
doi:
Substances chimiques
Narcotics
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1541-1546Références
Arzneimittelforschung. 2003;53(10):681-7
pubmed: 14650359
Drug Alcohol Depend. 1991 Jan;27(1):7-17
pubmed: 2029860
Pharmacol Biochem Behav. 2010 Sep;96(3):279-86
pubmed: 20580909
Crit Care Clin. 2010 Jul;26(3):527-47, x
pubmed: 20643305
Arch Intern Med. 2012 Mar 12;172(5):425-30
pubmed: 22412106
World J Surg. 2013 Feb;37(2):259-84
pubmed: 23052794
Br J Surg. 2013 Mar;100(4):482-9
pubmed: 23339040
Obes Surg. 2014 May;24(5):753-8
pubmed: 24357126
BMJ. 2014 Feb 11;348:g1251
pubmed: 24519537
Obes Surg. 2015 Sep;25(9):1639-46
pubmed: 25670530
Med Sci Monit. 2015 Mar 17;21:791-7
pubmed: 25779669
Surgery. 2015 Jun;157(6):1130-6
pubmed: 25791027
Surg Obes Relat Dis. 2016 Jan;12(1):119-26
pubmed: 25892343
Obes Surg. 2016 Feb;26(2):303-12
pubmed: 26003552
Am J Orthop (Belle Mead NJ). 2015 Oct;44(10 Suppl):S5-8
pubmed: 26447431
J Psychiatr Res. 2016 May;76:16-29
pubmed: 26871733
Schweiz Med Wochenschr. 1989 Dec 9;119(49):1777-80
pubmed: 2694367
Obes Surg. 2017 Jan;27(1):226-235
pubmed: 27817086
Obes Surg. 2017 Feb;27(2):489-501
pubmed: 27878754
JAMA Surg. 2017 Jul 1;152(7):691-697
pubmed: 28564673
MMWR Morb Mortal Wkly Rep. 2017 Jul 07;66(26):697-704
pubmed: 28683056
Surg Obes Relat Dis. 2018 Jun;14(6):849-856
pubmed: 29555468
JAMA Surg. 2018 Aug 1;153(8):757-763
pubmed: 29799927
Am J Surg. 2018 Oct;216(4):652-657
pubmed: 30041735
Surgery. 2018 Oct;164(4):674-679
pubmed: 30098812
Br J Anaesth. 1997 May;78(5):606-17
pubmed: 9175983